Research programme: vaccine therapeutics - Liquidia TechnologiesAlternative Names: Multivalent PRINT nanoparticle pneumococcal vaccine - Liquidia Technologies
Latest Information Update: 14 Mar 2014
At a glance
- Originator Liquidia Technologies
- Developer Liquidia Technologies; Malaria Vaccine Initiative; PATH
- Class Bacterial vaccines; Cancer vaccines; Influenza virus vaccines; Pneumococcal vaccines; Synthetic vaccines; Vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer; Infections; Influenza virus infections; Pneumococcal infections
- Research Malaria